These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2377 related articles for article (PubMed ID: 23470321)

  • 41. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
    Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
    Front Immunol; 2021; 12():750478. PubMed ID: 34912334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early T cell receptor signals globally modulate ligand:receptor affinities during antigen discrimination.
    Pielak RM; O'Donoghue GP; Lin JJ; Alfieri KN; Fay NC; Low-Nam ST; Groves JT
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12190-12195. PubMed ID: 29087297
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Signals and sequences that control CD28 localization to the central region of the immunological synapse.
    Sanchez-Lockhart M; Graf B; Miller J
    J Immunol; 2008 Dec; 181(11):7639-48. PubMed ID: 19017952
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M; Fallarino F; Zhou P; Frauwirth K; Thistlethwaite J; Newell K; Gajewski T; Bluestone J
    Transplant Proc; 2001; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract]   [Full Text] [Related]  

  • 45. CD28/B7-mediated co-stimulation is critical for early control of murine cytomegalovirus infection.
    Cook CH; Chen L; Wen J; Zimmerman P; Zhang Y; Trgovcich J; Liu Y; Gao JX
    Viral Immunol; 2009 Apr; 22(2):91-103. PubMed ID: 19326996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD28/B7 costimulation: a review.
    Greenfield EA; Nguyen KA; Kuchroo VK
    Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of the CD28-CD80 co-stimulation signal by a CD28-binding affibody ligand developed by combinatorial protein engineering.
    Sandström K; Xu Z; Forsberg G; Nygren PA
    Protein Eng; 2003 Sep; 16(9):691-7. PubMed ID: 14560055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling.
    Porciello N; Tuosto L
    Cytokine Growth Factor Rev; 2016 Apr; 28():11-9. PubMed ID: 26970725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The complexities of T-cell co-stimulation: CD28 and beyond.
    Sperling AI; Bluestone JA
    Immunol Rev; 1996 Oct; 153():155-82. PubMed ID: 9010723
    [No Abstract]   [Full Text] [Related]  

  • 50. New protein steals the show as 'costimulator' of T cells.
    Cohen J
    Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
    [No Abstract]   [Full Text] [Related]  

  • 51. The critical role of CD28 signalling in the prevention of human T-cell anergy.
    Boussiotis VA; Freeman GJ; Gribben JG; Nadler LM
    Res Immunol; 1995; 146(3):140-9. PubMed ID: 8525043
    [No Abstract]   [Full Text] [Related]  

  • 52. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses.
    Crawford A; Wherry EJ
    Curr Opin Immunol; 2009 Apr; 21(2):179-86. PubMed ID: 19264470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CD28-CD80/86 and CD40-CD40L Interactions Promote Thymic Tolerance by Regulating Medullary Epithelial Cell and Thymocyte Development.
    Williams JA; Tai X; Hodes RJ
    Crit Rev Immunol; 2015; 35(1):59-76. PubMed ID: 25746048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NF-κB family of transcription factors: biochemical players of CD28 co-stimulation.
    Tuosto L
    Immunol Lett; 2011 Mar; 135(1-2):1-9. PubMed ID: 20863851
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.
    Linsley PS; Ledbetter J; Peach R; Bajorath J
    Res Immunol; 1995; 146(3):130-40. PubMed ID: 8525042
    [No Abstract]   [Full Text] [Related]  

  • 56. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular pathway profiling of T lymphocyte signal transduction pathways; Th1 and Th2 genomic fingerprints are defined by TCR and CD28-mediated signaling.
    Smeets RL; Fleuren WW; He X; Vink PM; Wijnands F; Gorecka M; Klop H; Bauerschmidt S; Garritsen A; Koenen HJ; Joosten I; Boots AM; Alkema W
    BMC Immunol; 2012 Mar; 13():12. PubMed ID: 22413885
    [TBL] [Abstract][Full Text] [Related]  

  • 58. What's the difference between CD80 and CD86?
    Sansom DM; Manzotti CN; Zheng Y
    Trends Immunol; 2003 Jun; 24(6):314-9. PubMed ID: 12810107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM; Noel PJ; Sperling AI; Walunas TL; Gray GS; Bluestone JA; Thompson CB
    Immunity; 1994 Sep; 1(6):501-8. PubMed ID: 7534617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.
    Bennett F; Luxenberg D; Ling V; Wang IM; Marquette K; Lowe D; Khan N; Veldman G; Jacobs KA; Valge-Archer VE; Collins M; Carreno BM
    J Immunol; 2003 Jan; 170(2):711-8. PubMed ID: 12517932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 119.